A Phase 3 interventional study of 9vHPV vaccine in Papillomavirus Infections, sponsored by Merck Sharp & Dohme LLC. Completed at 12 sites in Japan. Open to participants aged 9 Years to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-30.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections — 10 open to participants now, 20 under way, 8 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Papillomavirus Infections.
Among the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, this one is the 21st largest by enrollment, is one of 4 that started in 2021, is one of 16 in phase 3, and was the 16th registered.
580 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.
Browse Papillomavirus Infections studies →10 of the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections are open now, in 9 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in China
Ages 10–45 · Women only · Healthy volunteers
Indiana University · Sites in Kenya
Ages 9–49 · Women only · Healthy volunteers
Western Institute for Veterans Research · Sites in United States
Ages 18+
Talia Sainz Costa · Sites in Spain
Ages 9–18 · Healthy volunteers
Louisiana State University Health Sciences Center in New Orleans · Sites in United States
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →
Of the 87 Papillomavirus Infections studies recruiting now, 38 (44%) set no upper age limit and 44 (51%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 9 Years to 15 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 17 · Phase 4 10
First in 2009; this study’s year is marked. 4 started in 2021.
This study's enrollment of 314 is above the median of 229 across 404 interventional studies indexed under Papillomavirus Infections.
Median enrollment 700 across the 31 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
38 studies in Papillomavirus Infections by Merck & Co., Inc: 1 open now, 7 under way, 6 of them phase 3. Of 30 finished, 26 (87%) have results posted.
Among the 38 studies in Papillomavirus Infections by Merck & Co., Inc, this one is the 23rd largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2021, is one of 26 in phase 3, and was the 34th registered.
Merck & Co., Inc’s Papillomavirus Infections studies by the year they started, since 2000.
3 of the studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04199689Phase 3Merck Sharp & Dohme LLCEfficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) | 2027-01-15 |
| NCT04206813Boston Medical CenterAn Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen | 2026-12 |
| NCT07303751Institut d'Investigació Biomèdica de BellvitgeStudy Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV | 2027-02-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, from their registry updates:
Among Merck & Co., Inc’s 38 in Papillomavirus Infections:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is the estimation of the human papillomavirus (HPV) 6, 11, 16, 18, 31, 33, 45, 52 and 58 seroconversion at 1 month post last dose (Month 7) following 3 doses and 2 doses of the 9-valent human papillomavirus (9vHPV) vaccine. No hypothesis will be tested since this study is an estimation-only study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
9 to 15 year old boys will receive a 3-dose regimen of 9vHPV vaccine (Day 1, Month 2 and Month 6).
Biological: 9vHPV vaccine
9 to 14 year old boys receive a 2-dose regimen of 9vHPV vaccine (Day 1 and Month 6).
Biological: 9vHPV vaccine
9 to 14 year old girls receive a 2-dose regimen of 9vHPV vaccine (Day 1 and Month 6).
Biological: 9vHPV vaccine
9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
Also known as: V503, SILGARD®9, GARDASIL™9
Seroconversion Percentages for the HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58
The percentage of seropositive participants is reported. Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using competitive Luminex Immunoassay (cLIA). Seroconversion was defined as changing serostatus from seronegative at Day 1 to seropositive at 4 weeks post last vaccination.
Time frame: 1 month after final dose (Month 7)
Number of Participants With at Least 1 Injection-site Adverse Event (AE)
The number of participants with injection-site AEs (erythema/redness, pain and swelling) is reported. An AE any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Time frame: Up to 5 days after each vaccination (up to ~6 months)
Number of Participants With at Least 1 Systemic Adverse Event
The number of participants with a systemic AE is reported. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Time frame: Up to 15 days after each vaccination (up to ~6.5 months)
Number of Participants With at Least 1 Serious Adverse Event (SAE)
The number of participants with an SAE is reported. An SAE is defined as one that results in death, is life threatening, or requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly or birth defect, or other important medical event that may require medical intervention.
Time frame: Up to ~Month 30
Geometric Mean Titers (GMTs) for the HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58
The GMT for each HPV serotype is presented. Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using competitive Luminex Immunoassay (cLIA).
Time frame: 1 month after final dose (Month 7)
| Milestone | 3-Dose Regimen: 9 to 15 Year Old Boys | 2-dose Regimen: 9 to 14 Year Old Boys | 2-dose Regimen: 9 to 14 Year Old Girls |
|---|---|---|---|
| Started | 105 | 104 | 105 |
| Completed | 101 | 104 | 104 |
| Not completed | 4 | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 | 1 |
The percentage of seropositive participants is reported. Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using competitive Luminex Immunoassay (cLIA). Seroconversion was defined as changing serostatus from seronegative at Day 1 to seropositive at 4 weeks post last vaccination.
| Percentage of Participants | 3-Dose Regimen: 9 to 15 Year Old Boys | 2-dose Regimen: 9 to 14 Year Old Boys | 2-dose Regimen: 9 to 14 Year Old Girls |
|---|---|---|---|
| Anti-HPV 6 | 100.0 (96.0 to 100.0) | 100.0 (96.0 to 100.0) | 100.0 (96.1 to 100.0) |
| Anti-HPV 11 | 100.0 (96.0 to 100.0) | 100.0 (96.0 to 100.0) | 100.0 (96.1 to 100.0) |
| Anti-HPV 16 | 100.0 (96.3 to 100.0) | 100.0 (96.3 to 100.0) | 100.0 (96.3 to 100.0) |
| Anti-HPV 18 | 100.0 (96.2 to 100.0) | 100.0 (96.1 to 100.0) | 100.0 (95.7 to 100.0) |
| Anti-HPV 31 | 100.0 (96.0 to 100.0) | 100.0 (96.1 to 100.0) | 100.0 (96.0 to 100.0) |
| Anti-HPV 33 | 100.0 (95.8 to 100.0) | 100.0 (96.0 to 100.0) | 100.0 (96.2 to 100.0) |
| Anti-HPV 45 | 100.0 (96.2 to 100.0) | 100.0 (96.2 to 100.0) | 100.0 (96.3 to 100.0) |
| Anti-HPV 52 | 100.0 (96.3 to 100.0) | 100.0 (96.2 to 100.0) | 100.0 (96.3 to 100.0) |
| Anti-HPV 58 | 100.0 (96.4 to 100.0) | 100.0 (96.4 to 100.0) | 100.0 (96.3 to 100.0) |
The number of participants with injection-site AEs (erythema/redness, pain and swelling) is reported. An AE any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
| Participants | 3-Dose Regimen: 9 to 15 Year Old Boys | 2-dose in 9 to 14 Year Old Boys | 2-dose in 9 to 14 Year Old Girls |
|---|---|---|---|
| Number of Participants With at Least 1 Injection-site Adverse Event (AE) | 87 | 85 | 92 |
The number of participants with a systemic AE is reported. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
| Participants | 3-Dose Regimen: 9 to 15 Year Old Boys | 2-dose in 9 to 14 Year Old Boys | 2-dose in 9 to 14 Year Old Girls |
|---|---|---|---|
| Number of Participants With at Least 1 Systemic Adverse Event | 55 | 41 | 33 |
The number of participants with an SAE is reported. An SAE is defined as one that results in death, is life threatening, or requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly or birth defect, or other important medical event that may require medical intervention.
| Participants | 3-Dose Regimen: 9 to 15 Year Old Boys | 2-dose Regimen: 9 to 14 Year Old Boys | 2-dose Regimen: 9 to 14 Year Old Girls |
|---|---|---|---|
| Number of Participants With at Least 1 Serious Adverse Event (SAE) | 0 | 2 | 3 |
The GMT for each HPV serotype is presented. Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using competitive Luminex Immunoassay (cLIA).
| GMT (mMU/mL) | 3-Dose Regimen: 9 to 15 Year Old Boys | 2-dose Regimen: 9 to 14 Year Old Boys | 2-dose Regimen: 9 to 14 Year Old Girls |
|---|---|---|---|
| Anti-HPV 6 | 1759.8 (1481.2 to 2090.8) | 2417.0 (2057.3 to 2839.6) | 2343.2 (2036.1 to 2695.5) |
| Anti-HPV 11 | 1341.8 (1136.1 to 1584.9) | 1510.1 (1310.3 to 1740.4) | 1508.5 (1340.8 to 1697.0) |
| Anti-HPV 16 | 7020.8 (5955.3 to 8277.1) | 9808.5 (8437.7 to 11402.0) | 9800.0 (8440.1 to 11379.1) |
| Anti-HPV 18 | 2629.6 (2154.7 to 3209.1) | 2464.6 (2095.6 to 2898.5) | 2999.8 (2509.3 to 3586.3) |
| Anti-HPV 31 | 2095.0 (1717.2 to 2555.9) | 1908.5 (1619.3 to 2249.4) | 1838.7 (1571.8 to 2151.0) |
| Anti-HPV 33 | 894.9 (753.1 to 1063.4) | 1272.1 (1085.2 to 1491.2) | 1283.1 (1132.4 to 1453.8) |
| Anti-HPV 45 | 848.9 (701.1 to 1027.8) | 508.4 (431.7 to 598.8) | 599.6 (520.6 to 690.4) |
| Anti-HPV 52 | 925.3 (774.9 to 1105.0) | 587.4 (503.3 to 685.5) | 582.7 (517.3 to 656.4) |
| Anti-HPV 58 | 1401.7 (1177.4 to 1668.8) | 1350.6 (1155.1 to 1579.1) | 1379.8 (1216.4 to 1565.1) |
Collected over Up to ~Month 30. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 3-Dose Regimen: 9 to 15 Year Old Boys | 0/103 (0%) | 0/103 (0%) | 18/103 (17.5%) |
| 2-dose Regimen: 9 to 14 Year Old Boys | 0/104 (0%) | 2/104 (1.9%) | 12/104 (11.5%) |
| 2-dose Regimen: 9 to 14 Year Old Girls | 0/104 (0%) | 3/104 (2.9%) | 8/104 (7.7%) |
| Event | 3-Dose Regimen: 9 to 15 Year Old Boys | 2-dose Regimen: 9 to 14 Year Old Boys | 2-dose Regimen: 9 to 14 Year Old Girls |
|---|---|---|---|
| Anaphylactic reactionImmune system disorders | 0/103 | 1/104 | 1/104 |
| Pyelonephritis acuteInfections and infestations | 0/103 | 0/104 | 1/104 |
| Tympanic membrane perforationEar and labyrinth disorders | 0/103 | 1/104 | 0/104 |
| StrabismusEye disorders | 0/103 | 0/104 | 1/104 |
| Event | 3-Dose Regimen: 9 to 15 Year Old Boys | 2-dose Regimen: 9 to 14 Year Old Boys | 2-dose Regimen: 9 to 14 Year Old Girls |
|---|---|---|---|
| PyrexiaGeneral disorders | 18/103 | 12/104 | 8/104 |
| HeadacheNervous system disorders | 10/103 | 9/104 | 6/104 |
| NasopharyngitisInfections and infestations | 6/103 | 3/104 | 4/104 |
| Age, Continuous(Years) | 3-Dose Regimen: 9 to 15 Year Old Boys | 2-dose Regimen: 9 to 14 Year Old Boys | 2-dose Regimen: 9 to 14 Year Old Girls | Total |
|---|---|---|---|---|
| Mean | 11.8 ± 2.0 | 11.5 ± 1.7 | 11.4 ± 1.6 | 11.6 ± 1.8 |
| Sex: Female, Male(Participants) | 3-Dose Regimen: 9 to 15 Year Old Boys | 2-dose Regimen: 9 to 14 Year Old Boys | 2-dose Regimen: 9 to 14 Year Old Girls | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 105 | 105 |
| Male | 105 | 104 | 0 | 209 |
| Ethnicity (NIH/OMB)(Participants) | 3-Dose Regimen: 9 to 15 Year Old Boys | 2-dose Regimen: 9 to 14 Year Old Boys | 2-dose Regimen: 9 to 14 Year Old Girls | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 105 | 104 | 105 | 314 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 3-Dose Regimen: 9 to 15 Year Old Boys | 2-dose Regimen: 9 to 14 Year Old Boys | 2-dose Regimen: 9 to 14 Year Old Girls | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 105 | 104 | 105 | 314 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from May 2021 to primary completion in Apr 2024, 34 months.
Results were first posted in May 2025, 1 year 1 month after primary completion.
Of 54 industry-sponsored phase 3 interventional studies under Papillomavirus Infections, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 64. This study's 34 months is above that.
Counting every sponsor, half of 60 studies reached it within 29 months; a quarter within 16 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent